MRI contrast agent

type of contrast agent used for magnetic resonance imaging

Uses your system voice; voice and rate in settings.

≈ 2 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

  • Françaisproduit de contraste pour imagerie par résonance
  • العربيةوسط تباين في التصوير بالرنين المغناطيسي
  • УкраїнськаКонтрастні речовини для МРТ
  • MagyarMRI kontrasztanyagok
  • DeutschMRT-Kontrastmittel
  • EnglishMRI contrast agent
  • 日本語MRI造影剤
  • 中文MRI造影剂

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

whose naturally high content in paramagnetic manganese allows it to be used as an MRI contrast agent MRI contrast agents are contrast agents used to improve the visibility of internal body structures in magnetic resonance imaging (MRI). The most commonly used compounds for contrast enhancement are gadolinium-based contrast agents (GBCAs).

Such MRI contrast agents shorten the relaxation times of nuclei within body tissues following oral or intravenous administration.

Gadolinium(III)

Gadolinium(III) containing MRI contrast agents (often termed simply "gado" or "gad") are the most commonly used for enhancement of vessels in MR angiography or for brain tumor enhancement associated with the degradation of the blood–brain barrier (BBB). Over 450 million doses have been administered worldwide from 1988 to 2017.

For large vessels such as the aorta and its branches, the dose can be as low as of body mass, or half that if gadopiclenol or gadoquatrane are used. Higher concentrations are often used for finer vasculature. At much higher concentration, there is more T2 shortening effect of gadolinium, causing gadolinium brightness to be less than surrounding body tissues.

However at such concentration, it will cause greater toxicity to bodily tissues. Gd 3+ chelates are hydrophilic and do not readily cross the intact blood–brain barrier. Thus, they are useful in enhancing lesions and tumors where the blood–brain barrier is compromised and the Gd(III) leaks out.

In the rest of the body, the Gd 3+ initially remains in the circulation but then distributes into the interstitial space or is eliminated by the kidneys. The first gadolinium-based contrast agent (GBCA), gadopentetate dimeglumine (Magnevist), was approved nearly simultaneously by the EMA and by the FDA in the late 1980's. (standard dose )): However, beginning in 2017, the EMA restricted several older linear gadolinium contrast agents that had previously been approved for human use in the EU.

See also

Lanthanide probes

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369909755 under CC BY-SA 4.0; modifications have been made.

Words in each sectionGadolinium(III)Gadolinium(III)Gadolinium(III): 242 words242See alsoSee alsoSee also: 23 words23
Words in each section. Measured from the stored article body; sections below the minimum are not plotted.

Provenance

snapshot mri-contrast-agent-759956-fa37c9b7aaeaa072 · hash fa37c9b7aaeaa072542604635ff6dc828393151997f73f0cb50f62f9cb41935f · captured 2026-08-17 · ledger · version history

Cite this page as: encyclopegia.org, “MRI contrast agent”, snapshot mri-contrast-agent-759956-fa37c9b7aaeaa072. https://encyclopegia.org/a/mri-contrast-agent

Sources cited in this revision

29 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.